#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group @RheumNow https://t.co/iucDK1GpU4

Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf

• Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort - Associati…

Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared to 2nd TNFi following failure of 1st TNFi. @RheumNow #ACR22 Abstr#2149 https://t.co/Er2FKwYdRv https://t.co/uMPSfMkjfa

• Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rhe…

#ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm

"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow

Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp

• Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Resul…

Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs

• Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients …

Black et al. Treat to target in gout. Monthly rheumatologist review and urate titration vs 6-monthly. 89% vs 40% at target ≤0.30mmol/L (<5mg/dl). SU decrease 38% vs 18%. US features also improved. @RheumNow #ACR22 Abstr#1579 https://t.co/TvxWAtl83y

• The TICOG Study: Tight Control of Gout - A Randomized, Controlled Trial of Targ…

#ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest https://t.co/swYn2g4hqe

#SLE mortality in South Carolina Lupus Cohort Standardized mortality ratio (SMR) is higher in blacks Higher SLICC scores in blacks abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc

Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU

• Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri…

Hoffmann-Vold. ILD in pSS. Frequently progressive - 21% FVC, 32% DLCO, 45% HRCT progression over 1 year. @RheumNow #ACR22 Abstr#2049 https://t.co/um3845jOFC https://t.co/64BEB2VyG0

• ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive - ACR …

New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML

Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L

• Association of Hydroxychloroquine with the Incidence of Infectious Disease in S…

Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5